Compare AERO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERO | URGN |
|---|---|---|
| Founded | 1934 | 2004 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2023 | 2016 |
| Metric | AERO | URGN |
|---|---|---|
| Price | $14.56 | $43.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $28.57 | ★ $29.29 |
| AVG Volume (30 Days) | 295.1K | ★ 985.0K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $11.85 | $129.09 |
| Revenue Next Year | $4.57 | $70.96 |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.26 | $15.86 |
| 52 Week High | $23.05 | $50.81 |
| Indicator | AERO | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 45.28 |
| Support Level | $13.15 | $18.25 |
| Resistance Level | $16.84 | $43.93 |
| Average True Range (ATR) | 0.68 | 1.82 |
| MACD | 0.01 | -0.90 |
| Stochastic Oscillator | 43.85 | 14.81 |
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.